- Q1 2024 Apellis Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2024$43.9 (-10.06%)Earnings
- Q4 2023 Apellis Pharmaceuticals Inc Earnings Call TranscriptFeb 27, 2024$69.35 (-3.32%)Earnings
- Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Apellis Pharmaceuticals Inc at Goldman Sachs Healthcare C-Suite Unscripted Conference TranscriptJan 04, 2024
- Apellis Pharmaceuticals Inc to Discuss the CHMP Trend Vote TranscriptDec 14, 2023
- Apellis Pharmaceuticals Inc at Evercore ISI HealthCONx Conference TranscriptNov 28, 2023
- Q3 2023 Apellis Pharmaceuticals Inc Earnings Call TranscriptNov 01, 2023$49.9 (+2.55%)Earnings
- Apellis Pharmaceuticals Inc at Robert W Baird Global Healthcare Conference TranscriptSep 12, 2023
- Apellis Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Apellis Pharmaceuticals Inc at Wells Fargo Healthcare Conference TranscriptSep 08, 2023
- Apellis Pharmaceuticals Inc at Citi BioPharma Conference TranscriptSep 06, 2023
- Q2 2023 Apellis Pharmaceuticals Inc Earnings Call TranscriptJul 31, 2023$25.75 (-19.58%)Earnings
- Apellis Pharmaceuticals Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Apellis Pharmaceuticals Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Q1 2023 Apellis Pharmaceuticals Inc Earnings Call TranscriptMay 04, 2023$84.37 (-0.76%)Earnings
- Apellis Pharmaceuticals Inc SYFOVRE FDA Approval Call TranscriptFeb 17, 2023
- Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Apellis Pharmaceuticals Inc at Bank of America Biotech SMID Cap Conference TranscriptDec 07, 2022
- Q3 2022 Apellis Pharmaceuticals Inc Earnings Call TranscriptNov 07, 2022$47.62 (-5.55%)Earnings
- Apellis Pharmaceuticals Inc at Bank of America Global Healthcare Conference TranscriptSep 16, 2022
- Apellis Pharmaceuticals Inc at Citi BioPharma Conference TranscriptSep 07, 2022
- Apellis Pharmaceuticals Inc Corporate Call TranscriptAug 24, 2022
- Q2 2022 Apellis Pharmaceuticals Inc Earnings Call TranscriptAug 08, 2022$62.33 (-1.58%)Earnings
- Apellis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- Apellis Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 09, 2022
- Apellis Pharmaceuticals Inc at Bank of America Healthcare Conference TranscriptMay 11, 2022
- Q1 2022 Apellis Pharmaceuticals Inc Earnings Call TranscriptMay 04, 2022$45.95 (+3.00%)Earnings
- Apellis Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 11, 2022
- Apellis Pharmaceuticals Inc DERBY and OAKS 18 Month Data Conference Call TranscriptMar 16, 2022
- Apellis Pharmaceuticals Inc at Cowen Health Care Conference (Virtual) TranscriptMar 09, 2022
- Q4 2021 Apellis Pharmaceuticals Inc Earnings Call TranscriptFeb 28, 2022$42.53Earnings
- Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- Apellis Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 10, 2021
- Q3 2021 Apellis Pharmaceuticals Inc Earnings Call TranscriptNov 08, 2021$33.69 (-1.35%)Earnings
- Apellis Pharmaceuticals Inc Announces results from Phase 3Â DERBY and OAKS TranscriptSep 09, 2021
- Q2 2021 Apellis Pharmaceuticals Inc Earnings Call TranscriptAug 09, 2021$62 (-2.18%)Earnings
- Apellis Pharmaceuticals Inc Research and Development Day - New York City and Virtually TranscriptJun 30, 2021
- Apellis Pharmaceuticals Inc at Bank of America NAPA Healthcare Conference TranscriptJun 16, 2021
- Apellis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Apellis Pharmaceuticals Inc EMPAVELI FDA Approval Call TranscriptMay 17, 2021
- Q1 2021 Apellis Pharmaceuticals Inc Earnings Call TranscriptApr 28, 2021$45.3 (-0.33%)Earnings
- Q4 2020 Apellis Pharmaceuticals Inc Earnings Call TranscriptFeb 25, 2021$45.05 (-2.49%)Earnings
- Apellis Pharmaceuticals Inc Virtual Investorm Meeting - Pegcetacoplan: Advancing the First Potential Treatment for Geographic Atrophy (GA) TranscriptJan 28, 2021
- Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- Apellis Pharmaceuticals Inc Sobi Strategic Collaboration Conference Call TranscriptOct 27, 2020
- Apellis Pharmaceuticals Inc The Evolution of Complement Targeted Therapies Panel at Stifel Immunology & Inflammation Summit (Virtual) TranscriptOct 01, 2020
- Apellis Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) - Fireside Chat TranscriptSep 10, 2020
- Apellis Pharmaceuticals Inc, Aerie Pharmaceuticals, Aldeyra Therapeutics, and ProQR Therapeutic at Citi BioPharma Conference (Virtual) - Panel TranscriptSep 10, 2020
- Apellis Pharmaceuticals Inc to Discuss Phase 3 PEGASUS Study Results - Conference Call TranscriptJun 12, 2020
- Apellis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Apellis Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 14, 2020
- Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 14, 2020
- Apellis Pharmaceuticals, Inc. - Special Call TranscriptJan 07, 2020
- Apellis Pharmaceuticals Inc at Morgan Stanley Healthcare Conference TranscriptSep 09, 2019
- Editas Medicine Inc, Apellis Pharmaceuticals Inc and Rigel Pharmaceuticals Inc at Citi Biotech Conference TranscriptSep 05, 2019
Apellis Pharmaceuticals Inc at Robert W Baird Global Healthcare Conference Transcript
All right. Good afternoon, everyone. Thanks for being with us for Baird's Global Healthcare Conference. I'm Colleen Kusy, one of the senior analysts covering biotech at Baird. It is my pleasure to have with us Apellis Pharmaceuticals CEO and Co-Founder, Cedric Francois, and CFO, Tim Sullivan. Thanks for being with us, guys. So Cedric, I'll turn it off to you to give some opening remarks.
Well, thank you, Colleen. Thank you for inviting us. I'm very happy to be back again. So yes, it was a very busy summer for us, of course, and a very intense year, lots of emotions. I'm going to start off with what really stood out this summer for us and that's the fact that we got the updated data on SYFOVRE, where we continue to see increasing effects over time with slowdowns as much as 45% between month 24 and 30. That means that if you are a patient with geographic atrophy, who
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)